Table 1.
Agreement between predicted outcomes and gel assays
| Antibodies | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Serum/plasma | Agglutinins 2017 | Hemolysins 2017 | Previous screening (if different) | 1 AbCa Ua | 2 AbCa PaUa | 3 AaCaK aQcUa | 4 AaCa PaUa | 5 AaCa Qabc | 6 AaCa KaPa Ua | 7 AbCa Qc | 8 AabKa Ua | 9 AbKa Ua | 10 AbCa KaUa | 11 AaKa Ua | 12 AbCa Ka |
| P‐R‐M | P‐R‐M | P‐R‐M | P‐R‐M | P‐R‐M | P‐R‐M | P‐R‐M | P‐R‐M | P‐R‐M | P‐R‐M | P‐R‐M | P‐R‐M | ||||
| 1 | ‐ | ‐ | Same | C‐C‐C | C‐I‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐I‐C | C‐C‐C | C‐I‐C |
| 2 | Anti‐Aa Anti‐dk | ‐ | No Ab | C‐C‐C | C‐CC | I‐C‐I | I‐C‐C | I‐C‐I | I‐C‐I | C‐C‐C | I‐C‐C | C‐C‐C | C‐C‐C | I‐C‐C | C‐C‐C |
| 3 | Anti‐dk | ‐ | No Ab | C‐C‐C | C‐C‐C | C‐C‐C | C‐I‐C | C‐C‐C | C‐I‐C | C‐I‐C | C‐C‐C | C‐I‐C | C‐I‐C | C‐C‐C | C‐I‐C |
| 4 | ‐ | ‐ | Same | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C |
| 5 | ‐ | ‐ | Anti‐X | C‐C‐C | C‐I‐I | C‐C‐I | C‐C‐I | C‐C‐C | C‐C‐C | C‐C‐I | C‐C‐C | C‐C‐C | C‐C‐I | C‐C‐I | C‐C‐I |
| 6 | Anti‐X | ‐ | Same | U‐C‐C | U‐I‐Ca | U‐C‐C | U‐C‐Ia | U‐C‐C | C‐C‐C | U‐C‐C | U‐C‐C | U‐C‐Ia | U‐C‐C | U‐C‐C | U‐C‐C |
| 7 | ‐ | ‐ | Anti‐Aa Anti‐Ac |
C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐I | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C |
| 8 | Anti‐Ca Anti‐X |
Anti‐Ca | Same | I‐I‐I | I‐I‐I | I‐I‐I | I‐I‐I | I‐I‐I | I‐I‐I | I‐I‐I | C‐C‐C | U‐C‐Ia | I‐I‐I | U‐C‐C | I‐I‐I |
| 9 | Anti‐Ca Anti‐X |
Anti‐Ca | Same | I‐I‐I | I‐I‐I | I‐I‐I | I‐I‐I | I‐I‐I | I‐I‐I | I‐I‐I | U‐C‐C | C‐C‐C | I‐I‐I | U‐C‐C | I‐I‐I |
| 10 | ‐ | ‐ | Anti‐X | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C | C‐C‐C |
| 11 | Anti‐Ca | Anti‐Ca | I‐I‐I | I‐I‐I | I‐I‐I | I‐I‐I | I‐I‐I | I‐I‐I | I‐I‐I | C‐C‐C | C‐C‐C | I‐I‐I | C‐C‐C | I‐I‐I | |
1 to 12 indicates horse identification with their respective blood antigens and antibodies. The plasma/serum from horse 12 was excluded from analysis because of consistently positive auto‐controls with the rapid gel assay. ‐ indicates no antibodies. Same indicates that the antibodies in the previous screening were the same as in the 2017 screening. Gray background emphasizes discordant results between rapid gel or microgel assays and predicted results. Superscript letter “a” identifies discordant results between the 2 gel assays for which the prediction was unknown (ie, unidentified antibodies).
Abbreviations: Ab, antibody; Anti‐dk, anti‐donkey antibody; Anti‐X, unidentified antibody; C, compatible; I, incompatible; P‐R‐M, results for predicted compatibility, rapid gel assay, and microgel assay; U, unknown (because of the presence of an unidentified antibody).